NEW YORK – Bioinformatics company GenomOncology said on Monday that it has partnered with diagnostics firm Chronetyx Laboratories to reduce the turnaround time for sequencing-based cancer testing.
The partners plan to integrate GenomOncology's tertiary analysis and clinical genomic reporting platform Pathology Workbench with Chronetyx's next-gen sequencing and informatics systems. Specifically, they will support Chronetyx's Cyx Solid Tumor 505 comprehensive genomic profiling test, which is US Food and Drug Administration-cleared and CE-IVD-marked.
The integration will streamline data entry and analysis, speed up results delivery, automate the identification and prioritization of clinically significant findings, provide standardized reports that integrate with electronic health records, and support collaboration between pathologists, oncologists, and other healthcare providers.
"Our partnership with GenomOncology transforms how quickly we can deliver crucial genomic insights to physicians," Tim Hodge, president of Memphis, Tennessee-based Chronetyx, said in a statement.
"By streamlining the testing workflow and automating complex genomic analysis, we're helping ensure that patients receive the right treatment at the right time, based on the genetic profile of the patient's tumor," added Garreth Hippe, chief commercial officer of Cleveland, Ohio-based GenomOncology.